Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

1. A chimeric monoclonal antibody which recognizes CEACAM1 comprising a heavy chain sequence set forth in SEQ ID NO: 30 and a light chain sequence set forth in SEQ ID NO: 31.

2. The chimeric monoclonal antibody of claim 1 , produced from DNA sequences of the heavy and light chains contained in a plasmid deposited on Sep. 28, 2011 under ATCC Accession Number PTA-12130.

3. An isolated polynucleotide encoding the chimeric monoclonal antibody according to claim 1 .

4. A plasmid comprising at least one isolated polynucleotide sequence according to claim 3 .

5. A plasmid according to claim 4 , deposited on Sep. 28, 2011 under ATCC Accession Number PTA-12130.

6. A pharmaceutical composition comprising a therapeutically effective amount of the chimeric monoclonal antibody according to claim 1 ; and a pharmaceutically acceptable carrier.

7. A diagnostic composition comprising at least one chimeric monoclonal antibody according to claim 1 ; and an optional carrier or excipient.

8. A method of attenuating or treating a disease or disorder associated with expression, activation or function of CEACAM, comprising administering the pharmaceutical composition of claim 6 to a subject in need thereof.

9. The method of claim 8 , wherein the disease or disorder is a CEACAM1-expressing cancer.

10. The method of claim 8 , wherein the disease or disorder is a viral infection that increases expression of CEACAM1.

11. The method according to claim 8 , wherein the chimeric monoclonal antibody contained in the pharmaceutical composition is attached to a cytotoxic moiety and the disease is cancer.

12. The method of claim 8 , further comprising administering to the subject CEACAM1-expressing lymphocytes.

13. The method of claim 12 wherein the lymphocytes comprise T cells, NK cells or Tumor Infiltrating Lymphocyte.

14. A method of immunomodulation, the method comprising contacting a CEACAM-expressing lymphocyte with the antibody according to claim 1 .

15. A method of inhibiting migration of a CEACAM expressing tumor cell, the method comprising contacting the CEACAM expressing tumor cell with the antibody according to claim 1 , thereby inhibiting migration of a CEACAM expressing tumor cell.

16. A method of inhibiting CEACAM homotypic or heterotypic protein-protein interaction, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody according to claim 1 , thereby inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction.

17. A method for increasing the duration or progression of response or survival of a subject having a CEACAM1-expressing cancer, comprising administering to the subject effective amounts of a composition comprising a monoclonal antibody according to claim 1 , and an anti-neoplastic composition, wherein said antineoplastic composition comprises at least one chemotherapeutic agent, whereby the co-administration of the antibody and the anti-neoplastic composition effectively increases the duration or progression of survival.

18. A method for diagnosing a cancer in a subject in need thereof, the method comprising contacting a biological sample derived from the subject with the diagnostic composition of claim 7 , wherein a complex formation beyond a predetermined threshold is indicative of the cancer in the subject.

19. A method for diagnosing a disease or disorder associated with CEACAM expression, comprising the steps of:

i. incubating a biological sample with a monoclonal antibody according to claim 1 ;

ii. detecting the bound CEACAM using a detectable probe;

iii. comparing the amount of (ii) to a standard curve obtained from reference samples containing known amounts of CEACAM;

iv. calculating the amount of the CEACAM in the biological sample from the standard curve; and

v. comparing the amount of (iv) to a normal CEACAM amount.